Thymia Pitch Deck: All 9 Slides + Teardown

Slide 1: Title Slide

The deck opens with a clean, branded title slide. It features the company name, 'thymia,' and the tagline: 'Making mental health as objectively measurable as physical health.' The visual includes a stylized illustration of a person using a mobile device for a video call, with overlays suggesting facial tracking and voice analysis. This immediately establishes the company's focus on digital, objective assessment.

Slide 2: The Macro Problem

Slide 2 addresses 'Poor Mental Health' as a 'Huge societal & economic problem.' The slide uses a series of circles to highlight staggering statistics: a '$6 Trillion Problem,' '1 billion people affected,' and '8 Million Deaths.' It also notes that COVID doubled rates and that it takes an average of '10+ years to diagnosis & treatment.' Crucially, it points out a clinical failure: 'Less than 50% of generalist doctors successfully diagnose mental illness.' This sets a high-stakes stage for a technological intervention.

Slide 3: The Tooling Gap

This slide contrasts physical health and mental health to highlight a lack of objective tools. On the left, physical health is shown as predictable and treatable thanks to objective measurements (thermometers, blood tests, stethoscopes). On the right, mental health is depicted with 'X' marks over those same tools, stating: 'There are NO objective tools. Symptoms can be targeted only via subjective, inaccurate, biased questionnaires, outdated by a century.' This slide effectively defines the 'enemy' as the status quo of subjective reporting.

Slide 4: The Solution Analogy

Thymia introduces its solution by doubling down on the physical health analogy. Slide 4 explicitly states: 'thymia ≈ A blood pressure cuff.' It claims to make mental health 'objectively measurable and trackable as physical health.' By comparing their complex AI to a common, understood medical device, they simplify the value proposition for investors: they are building the standard diagnostic hardware (or software equivalent) for the brain.

Slide 5: The Team

The team slide is a significant strength for a Seed-stage deep tech company. It features four leaders, three of whom hold PhDs. CEO Emilia Molimpakis has over 12 years of experience with cognitive biomarkers and a PhD from UCL. CTO Stefano Goria brings 17 years of experience in multi-modal models, including time as a quant at Citibank and J.P. Morgan. CSO Nick Cummins is described as a 'World-leading ML expert in signal processing for mood disorders' with over 2200 citations. COO Gabrielle Powell rounds out the group with 13 years of finance and operations experience. The logos of UCL, University of Chicago, J.P. Morgan, and King's College London provide immediate institutional credibility.

Slide 6: The Technology

Slide 6 provides a technical overview of how the system works. It describes a multimodal approach combining Voice (acoustics and linguistics), Video (camera data), and Behaviour (typing, swiping, reaction times). These inputs feed into an AI that detects and quantifies 'Symptoms' (fatigue, sleep, mood, attention, etc.) which then map to 'Conditions' (Major Depression, Generalised Anxiety, ADHD). The slide emphasizes that they deliver 'objective outputs compared against patient & healthy distributions,' suggesting a normative database against which users are measured.

Slide 7: The Product and Distribution

This slide explains the business model and delivery mechanism. Thymia’s models are 'packaged as APIs & Widgets,' allowing them to be 'deployable flexibly and scalably everywhere.' They explicitly state a 'B2B2C' strategy, showing how the 'thymia Symptom & Condition Scores' flow from their API into a 'Customer Website' or 'Customer App.' This indicates a platform-agnostic approach where they act as the intelligence layer for other health providers.

Slide 8: The Strategy

The long-term strategy is to 'Dominate clinical space within 5 years fueled by Regulatory Approval.' The slide shows a roadmap starting with the 'world’s largest clinically validated depression & fatigue datasets,' moving through 'Class I Regulatory Approval,' and finally 'Scaling in Target Market.' The target markets are segmented into Primary Care (GPs), Secondary Care (Psychiatrists), and Digital Healthcare (online-only providers). This slide signals that the company understands the regulatory moats required in MedTech.

Slide 9: The Route to Series A

The final slide sets clear milestones for the next 12-18 months, targeting 'Series A metrics by Q3 2024.' It lists four pillars: Revenue (scaling sales to hit targets by Oct '24), Users (deepening customer success), Product (5+ new symptoms in 5 new languages), and Defensibility (Medical Device Regulation & IP patents by Dec '24). This slide serves as a de facto roadmap for how the current investment will be used to reach the next valuation inflection point.

What Works in the Thymia Deck

The Analogy: Comparing AI neuropsychology to a 'blood pressure cuff' is brilliant. It takes a 'black box' technology and gives it a familiar, clinical utility that any investor can understand.

Technical Credibility: In the AI and Healthcare space, the 'who' is as important as the 'what.' Having three PhDs with specific expertise in the problem domain (neuroscience, signal processing, theoretical physics) makes the claim of 'world-leading' technology much more believable.

Multimodal Breadth: By showing that they track voice, video, and behavior, they differentiate themselves from simpler 'mood tracker' apps. The complexity of the inputs (Slide 6) suggests a higher barrier to entry for competitors.

Regulatory Focus: Many health-tech startups try to bypass regulation by staying in the 'wellness' category. Thymia leans into regulation as a 'fuel' for dominance, which appeals to institutional healthcare investors who value clinical validation.

What is Missing from the Thymia Deck

The Ask: The deck does not state how much money they are looking for or the terms of the round. While this is often handled in a separate document or conversation, its absence here leaves the narrative without a clear call to action.

Current Traction: While they mention having the 'world's largest datasets,' the deck is light on current commercial traction. There are no mentions of current pilot programs, revenue figures, or specific B2B partners already using the API.

Competitive Landscape: The deck claims their models are 'unlike those of any competitor' (Slide 6) but does not provide a competitive matrix or explain how they differ from other players in the digital phenotyping space (e.g., Mindstrong or Ellipsis Health).

Unit Economics: There is no mention of how the API is priced (per user, per call, or flat fee). For a B2B2C model, understanding the margin and pricing structure is critical for evaluating the revenue milestones on Slide 9.

Founder Takeaways

Use 'The Enemy' to frame your solution: Thymia spends two slides (2 and 3) defining the problem and the failure of current tools. By the time they introduce their solution, the reader is already convinced that the current way of doing things is broken.

Lead with your strongest asset: For Thymia, that is the team. If you have a high-pedigree founding group, don't hide them at the end of the deck. Slide 5 acts as a massive credibility boost that carries through the technical slides that follow.

Set a deadline for your next round: Slide 9 is a great example of 'forward-looking accountability.' By stating exactly what metrics they will hit by Q3 2024 to be ready for a Series A, they show investors they are thinking about the long-term capital strategy, not just the current check.

Simplify the complex: AI-powered neuropsychology is difficult to explain. Use visual flowcharts (Slide 6) and simple analogies (Slide 4) to ensure the core value proposition isn't lost in the technical jargon.